Sputnik V vaccine is launch in India by RDIF and Panacea Biotec: The Russian Direct Investment Fund (RDIF) and Panacea Biotec, an Indian pharmaceutical company, announced on Monday that development of the Sputnik V corona virus vaccine has begun in India. The first batch of COVID-19 vaccine developed at Panacea Biotec’s Baddi facility in Himachal Pradesh will be sent to the Gamaleya Center in Russia for quality control.
The first batch of doses generated at Panacea Biotec’s Baddi facility will be shipped to the Gamaleya Centre in Moscow for “quality control,” according to the announcement. The company’s facilities “comply with GMP requirements and are prequalified by the WHO (World Health Organization),” according to the statement. Full-scale development of the vaccine is expected to begin this summer.
The launch of Sputnik V production, according to Panacea Biotec’s Managing Director Dr Rajesh Jain, is a significant step forward in India’s fight against the virus. “We want to help bring a sense of normalcy back to people around the country and around the world together with RDIF,” he said. “This marks a significant move as we begin production of Sputnik V,” Panacea Biotec MD Rajesh Jain said of the progress.
We plan to work with RDIF to help people all over the country and the worlds reclaim their sense of normalcy. On April 12, 2021, Sputnik V was registered in India under the emergency use authorisation process, and coronavirus vaccination with the Russian vaccine began on May 14 – He Added
|Online Test Series||Click Here|
|To Join Whatsapp ||Click Here|
|To Subscribe Youtube||Click Here|
|To Join Telegram Channel||Click Here|
|Online Classes||Click Here|